Key result
ZNF307 overexpression ameliorated pressure overload-induced cardiac hypertrophy by inhibiting NF-κB signaling, whereas ZNF307 deletion exacerbated pathological hypertrophy and cardiac dysfunction.
Why the study?
Does ZNF307 overexpression prevent pressure overload-induced cardiac hypertrophy in mice?
Does ZNF307 overexpression prevent pressure overload-induced cardiac hypertrophy in mice?
ZNF307 acts as a negative regulator of pressure overload-induced cardiac hypertrophy by inhibiting the NF-κB signaling pathway, suggesting a potential therapeutic target for heart failure.
Answers are grounded in this paper and cite their sources.
ZNF307 modulation remains experimental in mice; leaves open its therapeutic relevance in human pressure overload hypertrophy.
Pathological cardiac hypertrophy is a key risk factor for heart failure. We found that the protein expression levels of the ZNF307 (zinc finger protein 307) were significantly increased in heart samples from both human patients with dilated cardiomyopathy and mice subjected to aortic banding. Therefore, we aimed to elucidate the role of ZNF307 in the development of cardiac hypertrophy and to explore the signal transduction events that mediate the effect of ZNF307 on cardiac hypertrophy, using cardiac-specific ZNF307 transgenic (ZNF307-TG) mice and ZNF307 global knockout (ZNF307-KO) mice. The results showed that the deletion of ZNF307 potentiated aortic banding–induced pathological cardiac hypertrophy, fibrosis, and cardiac dysfunction; however, the aortic banding–induced cardiac hypertrophic phenotype was dramatically diminished by ZNF307 overexpression in mouse heart. Mechanistically, the antihypertrophic effects mediated by ZNF307 in response to pathological stimuli were associated with the direct inactivation of NF-κB (nuclear factor-κB) signaling and blockade of the nuclear translocation of NF-κB subunit p65. Furthermore, the overexpression of a degradation-resistant mutant of IκBα (IκBα S32A/S36A ) reversed the exacerbation of cardiac hypertrophy, fibrosis, and dysfunction shown in aortic banding–treated ZNF307-KO mice. In conclusion, our findings demonstrate that ZNF307 ameliorates pressure overload–induced cardiac hypertrophy by inhibiting the activity of NF-κB–signaling pathway.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2017) studied Cardiac hypertrophy. ZNF307 overexpression vs. ZNF307 deletion / control was evaluated on Aortic banding-induced pathological cardiac hypertrophy, fibrosis, and cardiac dysfunction. ZNF307 overexpression ameliorated pressure overload-induced cardiac hypertrophy by inhibiting NF-κB signaling, whereas ZNF307 deletion exacerbated pathological hypertrophy and cardiac dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: